3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Carcinoma, Hepatocellular
8
Nasopharyngeal Carcinoma
7
Esophageal Neoplasms
6
Neoplasm Metastasis
5
Triple Negative Breast Neoplasms
4
Stomach Neoplasms
4
Melanoma
4
Advanced NSCLC
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Rectal Neoplasms
3
Pancreatic Neoplasms
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Neoplasms
2
Lung Neoplasms
2
Locally Advanced Rectal Cancer
2
Leukemia, Myeloid, Acute
2
Esophageal Squamous Cell Carcinoma
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Biliary Tract Neoplasms
2
Advanced Solid Tumors
2
Advanced Solid Tumor
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Interventions
regorafenib
1
enasidenib
1
capivasertib
1
abemaciclib
1
Weight-Bearing
1
Taxes
1
Standard of Care
1
Range of Motion, Articular
1
Paclitaxel
1
Immunoglobulin G
1
Immune Checkpoint Inhibitors
1
Disulfides
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Chondrosarcoma
×
Immune Checkpoint Inhibitors
×
Clear all
NCT04673942
2024-10-26
BETA-PRIME
EpicentRx, Inc.
Phase 2
Recruiting
140 enrolled